NABUMETONE Drug Patent Profile
✉ Email this page to a colleague
When do Nabumetone patents expire, and when can generic versions of Nabumetone launch?
Nabumetone is a drug marketed by Annora Pharma, Aurobindo Pharma Usa, Chartwell Molecules, Chartwell Rx, Copley Pharm, Epic Pharma Llc, Impax Labs Inc, Invagen Pharms, Lgm Pharma, Nostrum Labs Inc, Oxford Pharms, Sciegen Pharms Inc, and Watson Labs. and is included in thirteen NDAs.
The generic ingredient in NABUMETONE is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nabumetone
A generic version of NABUMETONE was approved as nabumetone by CHARTWELL RX on February 25th, 2002.
Summary for NABUMETONE
Recent Clinical Trials for NABUMETONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Federal University of São Paulo | Phase 4 |
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
University of Southern Denmark | N/A |
Pharmacology for NABUMETONE
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |